- Trials with a EudraCT protocol (45)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
45 result(s) found for: Cryotherapy.
Displaying page 3 of 3.
EudraCT Number: 2005-004941-33 | Sponsor Protocol Number: A6191007 | Start Date*: 2006-03-02 | |||||||||||
Sponsor Name:PFIZER | |||||||||||||
Full Title: A Phase 2 Study of the Efficacy and Safety of SU-014813 in Patients with Metastatic Breast Cancer | |||||||||||||
Medical condition: Locally Recurrent or Metastatic Breast Cancer MBC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000572-14 | Sponsor Protocol Number: EFC6088 (XRP9881B/2001) | Start Date*: 2004-10-08 | |||||||||||
Sponsor Name:Aventis Pharmaceuticals, Inc. (a subsidiary of sanofi-aventis group) | |||||||||||||
Full Title: Phase II multicenter, open label, non-randomized study of intravenous RPR109881 q 3 weeks in patients with metastatic breast cancer progressing after therapy with anthracyclines, taxanes, and capec... | |||||||||||||
Medical condition: Metastatic breast cancer patients after failure to anthracyclines, taxanes and capecitabine. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) IT (Completed) ES (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001784-13 | Sponsor Protocol Number: ISRCTN91422391 | Start Date*: 2014-12-29 | |||||||||||
Sponsor Name:Queen Mary University of London | |||||||||||||
Full Title: PROVENT: A randomised, double blind, placebo controlled feasibility study to examine the clinical effectiveness of aspirin and/or Vitamin D3 to prevent disease progression in men on active surveill... | |||||||||||||
Medical condition: Prostate cancer disease progression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004309-24 | Sponsor Protocol Number: A6181112 | Start Date*: 2007-05-02 | |||||||||||
Sponsor Name:Pfizer Inc., East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE IIIB, RANDOMIZED, ACTIVE CONTROLLED OPEN-LABEL STUDY OF SUNITINIB (SUTENT®) 37.5 MG DAILY VS IMATINIB MESYLATE 800 MG DAILY IN THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS... | |||||||||||||
Medical condition: TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) ES (Completed) FR (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003326-41 | Sponsor Protocol Number: 200719 | Start Date*: 2016-01-13 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: Randomized, Double-Blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor | |||||||||||||
Medical condition: Preterm Labour | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
